We reported a couple of months ago on important decisions in the Fourth Circuit that invalidated state laws in West Virginia and Maryland purporting to compel pharmaceutical manufacturers to deliver steeply discounted prescription medicines to unlimited numbers of pharmacies under the federal 340B drug discount program. Because the opinions created a circuit split on a
The Blog has always been interested in off-label use issues. We hope our readers are as well. Here are a couple of recent developments that have nothing in common except that they involve off-label issues.
The first is regulatory. On May 12, 2023, the FDA actually did something smart, a relative rarity for the current
In a pair of decisions, Express Scripts, Inc. v. Anne Arundel County, ___ A.3d ___, 2026 WL 797872 (Md. March 23, 2026), an opioid case, and Mayor & City Council of Baltimore v. B.P. P.L.C., ___ A.3d ___, 2026 WL 809501 (Md. March 24, 2025), a climate change case, the Supreme Court of
Keralink Intl., Inc. v. Stradis Healthcare, LLC, 2025 WL 1947764 (4th Cir. 2025), is a rare published appellate decision on common-law implied indemnity in the context of prescription medical product liability litigation. The case involves two commercial intermediate seller parties already held liable to a buyer of the product (corneal eyewash) that had been
Stop us if you have heard us say “stop us if you have heard this before.” Pelvic mesh cases on remand have often faced the harsh realities of procedural requirements and burdens of proof because transferee judges have treated them like individual cases rather than items in an inventory. Decisions about the impact of failure
Keralink Intl., Inc. v. Geri-Care Pharmaceuticals Corp., 2023 WL 2000999 (4th Cir. Feb. 15, 2023), is unusual because it is an affirmance of summary judgment in favor of the plaintiff.
Many years ago, we won a summary judgment on behalf of our big bank client, which was suing another big bank for failure to fulfill
This post is from the non-Dechert side of the blog.
Our latest Zantac litigation decision is not from the Florida MDL, but rather a standalone case in Maryland − Mayor & City Council of Baltimore v. GlaxoSmithKline, LLC, 2022 WL 537004 (Md. Cir. Jan. 28, 2022). It’s a split decision, and depending on which
If you are even a casual reader of this blog, you have probably come upon a post disparaging the rulings coming out of the In re BHR Hip Implant Products Liability Litigation. That court’s PMA preemption opinion made our worst decision list for 2018. It rendered an abysmal decision finding that failure-to-report claims
After getting off to a rocky start a few years ago on preemption, cases in the Birmingham hip MDL are falling like dominoes. And just like last week’s case, the decision in Sedgwick v. Smith & Nephew, Inc., 2021 U.S. Dist. LEXIS 157412 (D. Md. Aug. 19, 2021) falls apart at the summary
This blogger took last week off – from everything except some sand, the ocean, and drinks with little umbrellas. And books! Books set in the post-Civil War era (The Book of Lost Friends), in post-World War I (The Last Train to Key West), during World War II (The Only Woman